These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 9587683

  • 1. Endocrine therapy of prostate cancer.
    Bare RL, Torti FM.
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [Abstract] [Full Text] [Related]

  • 2. Hormone therapy in advanced prostate cancer.
    Forster TH, Stoffel F, Gasser TC.
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract] [Full Text] [Related]

  • 3. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
    Bolla M, de Reijke TM, Zurlo A, Collette L.
    Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
    [No Abstract] [Full Text] [Related]

  • 4. Hormone therapy of prostatic bone metastases.
    Huben RP.
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [Abstract] [Full Text] [Related]

  • 5. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ, Small EJ.
    Urology; 2003 Dec 29; 62 Suppl 1():87-94. PubMed ID: 14747046
    [Abstract] [Full Text] [Related]

  • 6. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM.
    Front Radiat Ther Oncol; 2002 Dec 29; 36():66-71. PubMed ID: 11842756
    [No Abstract] [Full Text] [Related]

  • 7. [Hormono-radiotherapy of non-metastatic prostate cancers].
    Richaud P, Mazeron JJ.
    Cancer Radiother; 2002 May 29; 6(3):175-82. PubMed ID: 12116843
    [Abstract] [Full Text] [Related]

  • 8. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B.
    Urology; 2003 Dec 29; 62 Suppl 1():79-86. PubMed ID: 14747045
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.
    Expert Opin Investig Drugs; 2006 Jul 29; 15(7):795-804. PubMed ID: 16787142
    [Abstract] [Full Text] [Related]

  • 10. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F, Pace M.
    In Vivo; 1993 Jul 29; 7(5):423-4. PubMed ID: 8110985
    [Abstract] [Full Text] [Related]

  • 11. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ, Radiation Therapy Oncology Group P-0014.
    Urology; 2003 Dec 29; 62 Suppl 1():95-101. PubMed ID: 14747047
    [Abstract] [Full Text] [Related]

  • 12. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.
    Urologia; 2010 Dec 29; 77(2):71-83. PubMed ID: 20890863
    [Abstract] [Full Text] [Related]

  • 13. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F, Dupont A, Belanger A.
    Important Adv Oncol; 1985 Dec 29; ():193-217. PubMed ID: 3916740
    [No Abstract] [Full Text] [Related]

  • 14. Neoadjuvant androgen suppression and external beam radiation therapy.
    Zietman AL, Smith CT.
    Front Radiat Ther Oncol; 2002 Dec 29; 36():87-98. PubMed ID: 11842759
    [No Abstract] [Full Text] [Related]

  • 15. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 2001 Jul 29; 28(7):917-26. PubMed ID: 11478140
    [Abstract] [Full Text] [Related]

  • 16. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J.
    Tunis Med; 2005 Dec 29; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract] [Full Text] [Related]

  • 17. The androgen receptor for the radiation oncologist.
    Quero L, Rozet F, Beuzeboc P, Hennequin C.
    Cancer Radiother; 2015 May 29; 19(3):220-7. PubMed ID: 25921704
    [Abstract] [Full Text] [Related]

  • 18. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A.
    Arch Esp Urol; 2002 Sep 29; 55(7):771-5. PubMed ID: 12380304
    [No Abstract] [Full Text] [Related]

  • 19. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S, Simon JM, Mazeron JJ.
    Bull Cancer; 2009 Mar 29; 96(3):261-70. PubMed ID: 19318304
    [Abstract] [Full Text] [Related]

  • 20. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R, Wouters W, Bruynseels J.
    J Steroid Biochem Mol Biol; 1996 Jan 29; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.